Stephen Mullennix

URGN

CHIEF OPERATING OFFICER · UROGEN PHARMA LTD. · CIK 0001764139

FILING MIX · LIFETIME45%/55%

BUYS

SELLS

TOTAL VALUE

$40.7K

COMPANIES

ACTIVE SINCE

Jan 2020

HOLDINGS NOW

10,084

AVG SELL PX

$28.25

Trades · vs SPY

Loading price series…

Performance · forward returns vs SPY

3 backtested trades · 8 horizonsHow are these numbers computed? →

Forward-return performance of every backtestable P/S trade by Stephen Mullennix, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.

HORIZON	TRADES	WIN RATE	INSIDER RETURN	SPY RETURN	MEAN EXCESS	MEDIAN EXCESS	T-STAT
7d	3	+33.33%	+2.18%	-0.75%	+2.93%	+4.47%	—
14d	3	+66.67%	+0.23%	-2.29%	+2.52%	+2.62%	—
30d	3	+33.33%	-14.32%	-8.97%	-5.35%	-2.06%	—
60d	3	+66.67%	-14.57%	-10.55%	-4.02%	+0.36%	—
90d	3	+100.00%	-8.98%	-4.25%	-4.74%	-1.40%	—
180d	3	+100.00%	-15.83%	+7.56%	-23.39%	-18.51%	—
1y	3	+100.00%	-13.02%	+29.04%	-42.06%	-39.23%	—
2y	3	+100.00%	-72.50%	+40.73%	-113.23%	-110.50%	—

How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.

Holdings over time

URGN · 10,084 shares · as of Apr 27, 2020

Trading cadence · quarterly flow

BUY ● SELL ●

2020

FLOW · 5 buys / 6 sellsCOVERAGE · 2 quarters

Form 4 filings · all activity

COMPANY	TYPE	SHARES	PRICE	VALUE	HELD AFTER	TRADE DATE	FILED	DETAILS
URGN UROGEN PHARMA LTD.	SALE Chief Operating Officer	145	$24.35	$3.5K	10,084	Apr 27, 2020	Apr 28, 2020 ↗	View →
URGN UROGEN PHARMA LTD.	PURCHASE Chief Operating Officer	417	—	—	10,229	Apr 26, 2020	Apr 28, 2020 ↗	View →
URGN UROGEN PHARMA LTD.	SALE Chief Operating Officer	417	—	—	2,917	Apr 26, 2020	Apr 28, 2020 ↗	View →
URGN UROGEN PHARMA LTD.	SALE Chief Operating Officer	1,759	—	—	7,037	Feb 14, 2020	Feb 18, 2020 ↗	View →
URGN UROGEN PHARMA LTD.	SALE Chief Operating Officer	612	$28.04	$17.2K	9,812	Feb 14, 2020	Feb 18, 2020 ↗	View →
URGN UROGEN PHARMA LTD.	PURCHASE Chief Operating Officer	1,759	—	—	10,424	Feb 14, 2020	Feb 18, 2020 ↗	View →
URGN UROGEN PHARMA LTD.	PURCHASEGRANT Stock grant	3,000	—	—	3,000	Jan 31, 2020	Feb 3, 2020 ↗	View →
URGN UROGEN PHARMA LTD.	PURCHASEGRANT Stock grant	15,000	—	—	15,000	Jan 31, 2020	Feb 3, 2020 ↗	View →
URGN UROGEN PHARMA LTD.	SALE Chief Operating Officer	684	$29.26	$20.0K	8,665	Jan 27, 2020	Jan 28, 2020 ↗	View →
URGN UROGEN PHARMA LTD.	SALE Chief Operating Officer	1,666	—	—	3,334	Jan 26, 2020	Jan 28, 2020 ↗	View →
URGN UROGEN PHARMA LTD.	PURCHASE Chief Operating Officer	1,666	—	—	9,349	Jan 26, 2020	Jan 28, 2020 ↗	View →

Other insiders · URGN

Loading peer insiders…

About this filer

CIK 0001764139

ROLE

Chief Operating Officer

PRIMARY

URGN

COMPANIES

ACTIVE SINCE

Jan 2020

MARKETPEEL · /INSIDER/0001764139DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE

Stephen Mullennix

The morning brief, before the bell.